This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://localhost/temp/predkladatel/
n11http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n8http://linked.opendata.cz/resource/domain/vavai/projekt/
n17http://linked.opendata.cz/ontology/domain/vavai/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
skoshttp://www.w3.org/2004/02/skos/core#
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n5http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F07%3A00019217%21RIV10-MZ0-14110___/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n10http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F07%3A00019217%21RIV10-MZ0-14110___
rdf:type
skos:Concept n17:Vysledek
dcterms:description
Feasibility and safety of vaccination with Id-protein loaded autologous dendritic cells was proved in patients with multiple myeloma under the GMP conditions. Adjuvant immunotherapy with antigen-loaded dendritic cells (DCs) represents a novel and relatively non-toxic treatment modality for multiple myeloma (MM). Malignant cells in MM produce a monoclonal immunoglobulin (idiotypic protein) which is considered a tumor-specific antigen and can be used for the induction of T lymphocytes. To enhance the anti-myeloma immune response, the idiotypic protein (Id-protein) can be loaded into autologous DCs and used for vaccination. Aims: The aim of this study was to evaluate DC-based vaccine preclinically and test the safety and the immune response of the vaccine in patients with MM. Patients and Methods: Pre-clinical testing was performed in 8 patients with MM. DC loaded with autologous myeloma cells were used for autologous T cell stimulation in vitro. Feasibility and safety of vaccination with Id-protein loaded autologous dendritic cells was proved in patients with multiple myeloma under the GMP conditions. Adjuvant immunotherapy with antigen-loaded dendritic cells (DCs) represents a novel and relatively non-toxic treatment modality for multiple myeloma (MM). Malignant cells in MM produce a monoclonal immunoglobulin (idiotypic protein) which is considered a tumor-specific antigen and can be used for the induction of T lymphocytes. To enhance the anti-myeloma immune response, the idiotypic protein (Id-protein) can be loaded into autologous DCs and used for vaccination. Aims: The aim of this study was to evaluate DC-based vaccine preclinically and test the safety and the immune response of the vaccine in patients with MM. Patients and Methods: Pre-clinical testing was performed in 8 patients with MM. DC loaded with autologous myeloma cells were used for autologous T cell stimulation in vitro.
dcterms:title
The preparation of monoclonal immunoglobulin loaded dendritic cells vaccine for myeloma patients under GMP conditions: preclinical and first clinical results of a phase I/II clinical trial. The preparation of monoclonal immunoglobulin loaded dendritic cells vaccine for myeloma patients under GMP conditions: preclinical and first clinical results of a phase I/II clinical trial.
skos:prefLabel
The preparation of monoclonal immunoglobulin loaded dendritic cells vaccine for myeloma patients under GMP conditions: preclinical and first clinical results of a phase I/II clinical trial. The preparation of monoclonal immunoglobulin loaded dendritic cells vaccine for myeloma patients under GMP conditions: preclinical and first clinical results of a phase I/II clinical trial.
skos:notation
RIV/00216224:14110/07:00019217!RIV10-MZ0-14110___
n4:aktivita
n13:P
n4:aktivity
P(NR8945)
n4:dodaniDat
n10:2010
n4:domaciTvurceVysledku
n11:1873172 n11:4954130 n11:5551579 n11:6522319 n11:9622748
n4:druhVysledku
n9:O
n4:duvernostUdaju
n6:S
n4:entitaPredkladatele
n5:predkladatel
n4:idSjednocenehoVysledku
443861
n4:idVysledku
RIV/00216224:14110/07:00019217
n4:jazykVysledku
n15:eng
n4:klicovaSlova
Multiple myeloma; Idiotype; Vaccination.
n4:klicoveSlovo
n12:Vaccination. n12:Multiple%20myeloma n12:Idiotype
n4:kontrolniKodProRIV
[7FAA9CA72403]
n4:obor
n7:FD
n4:pocetDomacichTvurcuVysledku
5
n4:pocetTvurcuVysledku
5
n4:projekt
n8:NR8945
n4:rokUplatneniVysledku
n10:2007
n4:tvurceVysledku
Očadlíková, Darina Zahradová, Lenka Hájek, Roman Michálek, Jaroslav Kovářová, Lucie
n14:organizacniJednotka
14110